US 11,806,329 B2
Treating iron deficiency with ferric carboxymaltose
Tobias Sidelmann Christensen, Roskilde (DK); Philip Schaffalitzky De Muckadell, Virum (DK); Lars Lykke Thomsen, Holte (DK); and Claes Christian Strom, Rungsted (DK)
Assigned to PHARMACOSMOS HOLDING A/S, Holbaek (DK)
Filed by PHARMACOSMOS HOLDING A/S, Holbaek (DK)
Filed on Mar. 1, 2021, as Appl. No. 17/187,992.
Application 17/187,992 is a division of application No. 16/822,911, filed on Mar. 18, 2020, granted, now 11,020,369.
Application 16/822,911 is a division of application No. PCT/EP2019/079528, filed on Oct. 29, 2019.
Claims priority of application No. 18203223 (EP), filed on Oct. 29, 2018; and application No. 18203818 (EP), filed on Oct. 31, 2018.
Prior Publication US 2021/0290587 A1, Sep. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7016 (2006.01); A61P 7/06 (2006.01); A61P 43/00 (2006.01); A61K 31/295 (2006.01)
CPC A61K 31/295 (2013.01) [A61P 7/06 (2018.01)] 34 Claims
 
1. A method of treating iron deficiency in a human subject, which comprises administering a dose followed by a further dose of ferric carboxymaltose to the subject, wherein:
a. the dose of ferric carboxymaltose contains 750 mg of elemental iron and the further dose of ferric carboxymaltose contains 750 mg of elemental iron; or
b. the dose of ferric carboxymaltose contains 1000 mg of elemental iron and the further dose of ferric carboxymaltose contains in the range of 500 mg to 1000 mg of elemental iron,
wherein the subject has a reduced risk for hypophosphatemia, wherein the subject having a reduced risk for hypophosphatemia has a normal serum phosphate level.